Intrathecal baclofen for generalized dystonia

Area of Science:

• Neurology
• Neurosurgery
• Physical Medicine and Rehabilitation

Background:

• Generalized dystonia is a debilitating neurological disorder.
• Severe cases often become refractory to conventional oral pharmacotherapy.
• Intrathecal baclofen therapy (ITB) offers an alternative for managing refractory symptoms.

Purpose of the Study:

• To evaluate the efficacy and safety of ITB in patients with severe generalized dystonia.
• To assess long-term outcomes and patient-reported improvements.
• To identify factors influencing treatment response.

Main Methods:

• Retrospective analysis of 86 patients (3-42 years) with generalized dystonia treated with ITB.
• Screening via continuous infusion or bolus injection followed by pump implantation in responders.
• Dystonia severity scoring and patient questionnaires assessed at baseline and follow-up intervals up to 24 months.

Main Results:

• 91-93% of patients responded to initial ITB screening.
• Significant reductions in dystonia scores observed at 3, 6, 12, and 24 months (p<0.005).
• Catheter placement at T4 or higher correlated with better outcomes (p=0.005).
• 92% maintained response at a median 29-month follow-up.
• 86% reported improved quality of life; 33% improved speech.
• Adverse events occurred in 26%, surgical complications in 38%.

Conclusions:

• ITB is a highly effective treatment for severe generalized dystonia refractory to oral medications.
• ITB offers significant long-term symptom control and functional improvement.
• While surgical complications exist, ITB is likely the treatment of choice for refractory cases.